RNA polymerase II, I and III subunit EGenealiases: RPABC1 · RPB5 · XAP4 · hRPB25 · hsRPB5
Q-omics provides the consensus-scored POLR2E profile across patient tissues and cancer cell-line models. POLR2E expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, POLR2E is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, POLR2E protein abundance shows 32,924 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, KIRC, and LSCC as cancer lineages where POLR2E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2E survival associations across molecular data types. POLR2E RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2E RNA expression–survival associations across cancer types. High POLR2E expression shows unfavorable associations in UVM, KICH and ACC, but favorable associations in SCLC, KIRC and THYM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for POLR2E RNA expression.
This table summarizes POLR2E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR2E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2E shows higher tumor expression in KIRC, COAD, KIRP, HNSC, LIHC and LUSC. The KIRC box plot shows higher POLR2E RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with POLR2E in patient tissues and cancer cell lines. In patient samples, POLR2E shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
